Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated:  3/27/2018
Columbia University Medical Center
mi
from
New York, NY
Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated: 3/27/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated:  3/27/2018
Banner University Medical Center
mi
from
Phoenix, AZ
Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated: 3/27/2018
Banner University Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated:  3/27/2018
Piedmont HealtCare
mi
from
Atlanta, GA
Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated: 3/27/2018
Piedmont HealtCare
mi
from
Atlanta, GA
Click here to add this to my saved trials
Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated:  3/27/2018
Mount Sinai Hosp
mi
from
New York, NY
Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated: 3/27/2018
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated:  3/27/2018
Memorial Hermann Texas Medical Center
mi
from
Houston, TX
Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated: 3/27/2018
Memorial Hermann Texas Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated:  3/27/2018
Intermountain Medical Center
mi
from
Murray, UT
Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated: 3/27/2018
Intermountain Medical Center
mi
from
Murray, UT
Click here to add this to my saved trials
Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated:  3/27/2018
University of Washington Medical Center
mi
from
Seattle, WA
Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated: 3/27/2018
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated:  3/27/2018
MedStar Washington Medical Center
mi
from
Washington,
Mitral Implantation of TRAnscatheter vaLves
The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.
Status: Enrolling
Updated: 3/27/2018
MedStar Washington Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Measuring Thoracic Impedance in Hemodialysis Patients With the u-Cor Monitoring System
Measuring Thoracic Impedance in Hemodialysis Patients With the µ-Cor System A Pre-Market Validation Study (MaTcH)
Status: Enrolling
Updated:  3/27/2018
DaVita Clinical Research
mi
from
Lakewood, CO
Measuring Thoracic Impedance in Hemodialysis Patients With the u-Cor Monitoring System
Measuring Thoracic Impedance in Hemodialysis Patients With the µ-Cor System A Pre-Market Validation Study (MaTcH)
Status: Enrolling
Updated: 3/27/2018
DaVita Clinical Research
mi
from
Lakewood, CO
Click here to add this to my saved trials
Measuring Thoracic Impedance in Hemodialysis Patients With the u-Cor Monitoring System
Measuring Thoracic Impedance in Hemodialysis Patients With the µ-Cor System A Pre-Market Validation Study (MaTcH)
Status: Enrolling
Updated:  3/27/2018
Orlando Clinical Research Center
mi
from
Orlando, FL
Measuring Thoracic Impedance in Hemodialysis Patients With the u-Cor Monitoring System
Measuring Thoracic Impedance in Hemodialysis Patients With the µ-Cor System A Pre-Market Validation Study (MaTcH)
Status: Enrolling
Updated: 3/27/2018
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Measuring Thoracic Impedance in Hemodialysis Patients With the u-Cor Monitoring System
Measuring Thoracic Impedance in Hemodialysis Patients With the µ-Cor System A Pre-Market Validation Study (MaTcH)
Status: Enrolling
Updated:  3/27/2018
DaVita Clinical Research
mi
from
Minneapolis, MN
Measuring Thoracic Impedance in Hemodialysis Patients With the u-Cor Monitoring System
Measuring Thoracic Impedance in Hemodialysis Patients With the µ-Cor System A Pre-Market Validation Study (MaTcH)
Status: Enrolling
Updated: 3/27/2018
DaVita Clinical Research
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)
Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)
Status: Enrolling
Updated:  3/28/2018
Eskenazi Health
mi
from
Indianapolis, IN
Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)
Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)
Status: Enrolling
Updated: 3/28/2018
Eskenazi Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)
Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)
Status: Enrolling
Updated:  3/28/2018
Indiana University Health Methodist Hospital
mi
from
Indianapolis, IN
Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)
Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)
Status: Enrolling
Updated: 3/28/2018
Indiana University Health Methodist Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated:  3/28/2018
Northwestern Medical Faculty Foundation, Div of Hematology/Oncology
mi
from
Chicago, IL
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated: 3/28/2018
Northwestern Medical Faculty Foundation, Div of Hematology/Oncology
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated:  3/28/2018
Mount Sinai School of Medicine
mi
from
New York, NY
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated: 3/28/2018
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated:  3/28/2018
Cliniques Universitaires Saint-Luc
mi
from
Brussels,
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated: 3/28/2018
Cliniques Universitaires Saint-Luc
mi
from
Brussels,
Click here to add this to my saved trials
Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
Identification of the Pathogenesis of Thrombotic Microangiopathy in the Allo Stem Cell Transplant Setting in Adults
Status: Enrolling
Updated:  3/28/2018
New York-Presbyterian Hospital
mi
from
New York, NY
Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
Identification of the Pathogenesis of Thrombotic Microangiopathy in the Allo Stem Cell Transplant Setting in Adults
Status: Enrolling
Updated: 3/28/2018
New York-Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
The Use of Serratus Block for Cardiac Surgery
The Use of Serratus Block for Cardiac Surgery
Status: Enrolling
Updated:  3/28/2018
New York University School of Medicine
mi
from
New York, NY
The Use of Serratus Block for Cardiac Surgery
The Use of Serratus Block for Cardiac Surgery
Status: Enrolling
Updated: 3/28/2018
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Home-based vs. Supervised Exercise for People With Claudication
Home-based vs. Supervised Exercise for Claudicants
Status: Enrolling
Updated:  3/30/2018
General Clinical Research Center, University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Home-based vs. Supervised Exercise for People With Claudication
Home-based vs. Supervised Exercise for Claudicants
Status: Enrolling
Updated: 3/30/2018
General Clinical Research Center, University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Cardiovascular and Neurohormonal Effects of Faster Atrial Pacing Rate
Cardiovascular and Neurohormonal Effects of Faster Atrial Pacing Rate for Six Hours in Patients With Congestive Heart Failure, Heart Rate <70 Beats Per Minute and Fluid Overload.
Status: Enrolling
Updated:  3/30/2018
Columbia University
mi
from
New York, NY
Cardiovascular and Neurohormonal Effects of Faster Atrial Pacing Rate
Cardiovascular and Neurohormonal Effects of Faster Atrial Pacing Rate for Six Hours in Patients With Congestive Heart Failure, Heart Rate <70 Beats Per Minute and Fluid Overload.
Status: Enrolling
Updated: 3/30/2018
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Low-Level Transcutaneous Vagus Stimulation in ST Segment Elevation Myocardial Infarction: TREAT MI Study
Low-Level Transcutaneous Vagus Stimulation in ST Segment Elevation Myocardial Infarction: TREATMI Study
Status: Enrolling
Updated:  3/30/2018
OUHSC
mi
from
Oklahoma City, OK
Low-Level Transcutaneous Vagus Stimulation in ST Segment Elevation Myocardial Infarction: TREAT MI Study
Low-Level Transcutaneous Vagus Stimulation in ST Segment Elevation Myocardial Infarction: TREATMI Study
Status: Enrolling
Updated: 3/30/2018
OUHSC
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Peripherally Inserted Central Catheter (PICC) Thrombosis: Reverse Taper Versus Non-tapered Catheters
Peripherally Inserted Central Catheter (PICC) Thrombosis: Reverse Taper Versus Non-tapered Catheters
Status: Enrolling
Updated:  3/30/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Peripherally Inserted Central Catheter (PICC) Thrombosis: Reverse Taper Versus Non-tapered Catheters
Peripherally Inserted Central Catheter (PICC) Thrombosis: Reverse Taper Versus Non-tapered Catheters
Status: Enrolling
Updated: 3/30/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis
A Randomized, Open Label, Pilot Study to Assess the Pharmacodynamics Using Vefiynow and VASP Assay; and Pharmacokinetics of Ticagrelor vs Clopidogrel in Patients Undergoing PCI With History of Fibrinolysis in 24-48 Hours
Status: Enrolling
Updated:  4/2/2018
Medical Center of South Arkansas
mi
from
El Dorado, AR
Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis
A Randomized, Open Label, Pilot Study to Assess the Pharmacodynamics Using Vefiynow and VASP Assay; and Pharmacokinetics of Ticagrelor vs Clopidogrel in Patients Undergoing PCI With History of Fibrinolysis in 24-48 Hours
Status: Enrolling
Updated: 4/2/2018
Medical Center of South Arkansas
mi
from
El Dorado, AR
Click here to add this to my saved trials
Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants
Dose-Ranging, Safety And Efficacy Of Cathflo(TM) Activase(R) (Alteplase) For The Treatment Of Central Catheter Occlusion In Neonates And Infants; Phase I
Status: Enrolling
Updated:  4/2/2018
University of Louisville
mi
from
Louisville, KY
Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants
Dose-Ranging, Safety And Efficacy Of Cathflo(TM) Activase(R) (Alteplase) For The Treatment Of Central Catheter Occlusion In Neonates And Infants; Phase I
Status: Enrolling
Updated: 4/2/2018
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
The BOSS Study: An Acute Evaluation of Anatomical and Geometric Changes Using the Bladder on a Stick System (BOSS)
An Acute Evaluation of Anatomical and Geometric Changes Using the Bladder on a Stick System (BOSS)
Status: Enrolling
Updated:  4/2/2018
Henry Ford Health System
mi
from
Detroit, MI
The BOSS Study: An Acute Evaluation of Anatomical and Geometric Changes Using the Bladder on a Stick System (BOSS)
An Acute Evaluation of Anatomical and Geometric Changes Using the Bladder on a Stick System (BOSS)
Status: Enrolling
Updated: 4/2/2018
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
The BOSS Study: An Acute Evaluation of Anatomical and Geometric Changes Using the Bladder on a Stick System (BOSS)
An Acute Evaluation of Anatomical and Geometric Changes Using the Bladder on a Stick System (BOSS)
Status: Enrolling
Updated:  4/2/2018
Minneapolis Heart Institute at Abbott Northwestern Hospital
mi
from
Minneapolis, MN
The BOSS Study: An Acute Evaluation of Anatomical and Geometric Changes Using the Bladder on a Stick System (BOSS)
An Acute Evaluation of Anatomical and Geometric Changes Using the Bladder on a Stick System (BOSS)
Status: Enrolling
Updated: 4/2/2018
Minneapolis Heart Institute at Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
The BOSS Study: An Acute Evaluation of Anatomical and Geometric Changes Using the Bladder on a Stick System (BOSS)
An Acute Evaluation of Anatomical and Geometric Changes Using the Bladder on a Stick System (BOSS)
Status: Enrolling
Updated:  4/2/2018
Sanatorio Italiano
mi
from
Asuncion,
The BOSS Study: An Acute Evaluation of Anatomical and Geometric Changes Using the Bladder on a Stick System (BOSS)
An Acute Evaluation of Anatomical and Geometric Changes Using the Bladder on a Stick System (BOSS)
Status: Enrolling
Updated: 4/2/2018
Sanatorio Italiano
mi
from
Asuncion,
Click here to add this to my saved trials
Longitudinal Study in Perimenopausal Women With Risk Factors for Atherosclerosis
Iron and Atherosclerosis: Longitudinal Study in Perimenopausal Women With Risk Factors for Atherosclerosis
Status: Enrolling
Updated:  4/3/2018
The Ohio State Univeristy Medical Center
mi
from
Columbus, OH
Longitudinal Study in Perimenopausal Women With Risk Factors for Atherosclerosis
Iron and Atherosclerosis: Longitudinal Study in Perimenopausal Women With Risk Factors for Atherosclerosis
Status: Enrolling
Updated: 4/3/2018
The Ohio State Univeristy Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Assessing Arrhythmias After Ablation Using Implantable Recorders
Assessment of Arrhythmia Burden in Patients Undergoing Atrial Fibrillation Using an Implantable Loop Recorder (ILR) Versus Conventional Monitoring Strategy
Status: Enrolling
Updated:  4/3/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Assessing Arrhythmias After Ablation Using Implantable Recorders
Assessment of Arrhythmia Burden in Patients Undergoing Atrial Fibrillation Using an Implantable Loop Recorder (ILR) Versus Conventional Monitoring Strategy
Status: Enrolling
Updated: 4/3/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction
Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure With Preserved Ejection Fraction
Status: Enrolling
Updated:  4/3/2018
Philadelphia VA Medical Center
mi
from
Philadelphia, PA
Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction
Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure With Preserved Ejection Fraction
Status: Enrolling
Updated: 4/3/2018
Philadelphia VA Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
Saadat Ansari MD LLC
mi
from
Huntsville, AL
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Saadat Ansari MD LLC
mi
from
Huntsville, AL
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
University of South Alabama Division of Clinical Research
mi
from
Mobile, AL
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
University of South Alabama Division of Clinical Research
mi
from
Mobile, AL
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
Heart Vascular of Northern Arizona
mi
from
COttonwood, AZ
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Heart Vascular of Northern Arizona
mi
from
COttonwood, AZ
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
Cardiovascular Associates of Mesa
mi
from
Mesa, AZ
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Associates of Mesa
mi
from
Mesa, AZ
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
Arizona Arthritis & Rheumatology Research PLLC
mi
from
Phoenix, AZ
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Arizona Arthritis & Rheumatology Research PLLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
Scottsdale Medical Imaging, Ltd
mi
from
Scottsdale, AZ
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Scottsdale Medical Imaging, Ltd
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
The Heart Clinic
mi
from
Scottsdale, AZ
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
The Heart Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
Pima Heart
mi
from
Tucson, AZ
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Pima Heart
mi
from
Tucson, AZ
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
Southern Arizona VA Health Care System
mi
from
Tucson, AZ
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Southern Arizona VA Health Care System
mi
from
Tucson, AZ
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
Arkansas Cardiology, PA
mi
from
Little Rock, AR
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Arkansas Cardiology, PA
mi
from
Little Rock, AR
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
Arkansas Heart Hospital
mi
from
Little Rock, AR
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Arkansas Heart Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
Medical Group of Culver City
mi
from
Culver City, CA
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Medical Group of Culver City
mi
from
Culver City, CA
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
Touro University California- Solano County Affiliated Clinics
mi
from
Fairfield, CA
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Touro University California- Solano County Affiliated Clinics
mi
from
Fairfield, CA
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
University California San Francisco
mi
from
Fresno, CA
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
University California San Francisco
mi
from
Fresno, CA
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
UCSD Sulpizio Cardiovascular Center
mi
from
La Jolla, CA
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
UCSD Sulpizio Cardiovascular Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
The University of California, San Diego
mi
from
La Jolla, CA
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
Kumar Medical Corporation
mi
from
Lancaster, CA
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Kumar Medical Corporation
mi
from
Lancaster, CA
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated:  4/3/2018
Loma Linda University Health
mi
from
Loma Linda, CA
Cardiovascular Inflammation Reduction Trial
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Loma Linda University Health
mi
from
Loma Linda, CA
Click here to add this to my saved trials